The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity

por Maurer, Mark F., Lewis, Katherine E., Kuijper, Joseph L., Ardourel, Dan, Gudgeon, Chelsea J., Chandrasekaran, Siddarth, Mudri, Sherri L., Kleist, Kayla N., Navas, Chris, Wolfson, Martin F., Rixon, Mark W., Swanson, Ryan, Dillon, Stacey R., Levin, Steven D., Kimbung, Yengo Raymond, Akutsu, Masato, Logan, Derek T., Walse, Björn, Swiderek, Kristine M., Peng, Stanford L.
Publicado 2022